ArticleGenetics and molecular biology2026
Protective effects of human umbilical cord mesenchymal stem cells-derived small extracelluar vesicles on corneal epithelial cells under hyperosmotic stress: Inhibition of oxidative damage and inflammation.
Article in Genetics and molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dry eye disease (DED) is often associated with corneal epithelial injury under hyperosmotic stress, which contributes to epithelial cell apoptosis and delay wound healing. Human Umbilical Cord Mesenchymal Stem Cell-derived Small Extracellular Vesicles (hUC-MSCs-sEVs) have emerged as promising therapeutic agents due to their anti-inflammatory, anti-apoptotic, and regenerative properties. In this study, we isolated and characterized hUC-MSCs-sEVs and assessed their therapeutic potential in hyperosmotic corneal epithelial injury. We demonstrated that hUC-MSCs-sEVs significantly promoted human corneal epithelial cell proliferation and repair under hyperosmotic conditions, reducing oxidative stress and preserving mitochondrial function. Additionally, hUC-MSCs-sEVs inhibited the expression of pro-inflammatory cytokines IL-6 and IL-1β, as well as downregulated the cGAS-STING signaling pathway, a critical mediator of inflammation. These findings suggest that hUC-MSCs-sEVs may offer a novel therapeutic strategy for treating hyperosmotic stress-induced corneal epithelial damage by mitigating oxidative stress, preserving mitochondrial integrity, and modulating inflammatory responses.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.